Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination

Authors

Chukiat Sirivichayakul, Faculty of Tropical Medicine, Mahidol University
Chukiat Sirivichayakul, Faculty of Tropical Medicine, Mahidol University
Shibadas Biswal
Shibadas Biswal
Xavier Saez-Llorens, Hospital del Niño Dr. José Renán Esquivel
Xavier Saez-Llorens, Hospital del Niño Dr. José Renán Esquivel
Eduardo López-Medina, Universidad del Valle, Cali
Eduardo López-Medina, Universidad del Valle, Cali
Charissa Borja-Tabora, Research Institute for Tropical Medicine
Charissa Borja-Tabora, Research Institute for Tropical Medicine
Lulu Bravo, University of the Philippines Manila
Lulu Bravo, University of the Philippines Manila
Pope Kosalaraksa, Faculty of Medicine, Khon Kaen University
Pope Kosalaraksa, Faculty of Medicine, Khon Kaen University
Maria Theresa Alera, Virology
Maria Theresa Alera, Virology
Humberto Reynales, Centro de Atención e Investigación Médica
Humberto Reynales, Centro de Atención e Investigación Médica
Luis Rivera, Hospital Maternidad Nuestra Senora de Altagracia
Luis Rivera, Hospital Maternidad Nuestra Senora de Altagracia
Veerachai Watanaveeradej, Phramongkutklao College of Medicine
Veerachai Watanaveeradej, Phramongkutklao College of Medicine
Delia Yu, De La Salle Medical and Health Sciences Institute
Delia Yu, De La Salle Medical and Health Sciences Institute
Felix Espinoza, National Autonomous University of Nicaragua, Leon
Felix Espinoza, National Autonomous University of Nicaragua, Leon
Reynaldo Dietze, Universidade Federal do Espírito Santo
Reynaldo Dietze, Universidade Federal do Espírito Santo
Lak Kumar Fernando, Negombo General Hospital
Lak Kumar Fernando, Negombo General Hospital
V. Pujitha Wickramasinghe, University of Colombo
Edson Duarte Moreira, Fundacao Oswaldo Cruz
Edson Duarte Moreira, Fundacao Oswaldo Cruz

Publication Date

12-15-2024

Document Type

Article

Publication Title

Journal of Infectious Diseases

Abstract

Background: We explored the impact of prior yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003. Methods: Children 4-16 years of age were randomized 2:1 to receive TAK-003 or placebo and were under active febrile surveillance. Symptomatic dengue was confirmed by serotype-specific reverse-transcription polymerase chain reaction. YF and JE vaccination history was recorded. Results: Of the 20 071 children who received TAK-003 or placebo, 21.1% had a YF and 23.9% had a JE vaccination history at randomization. Fifty-seven months after vaccination, vaccine efficacy (95% confidence interval) was 55.7% (39.7%-67.5%) in those with YF vaccination, 77.8% (70.8%-83.1%) for JE vaccination, and 53.5% (45.4%-60.4%) for no prior YF/JE vaccination. Regional differences in serotype distribution confound these results. The apparent higher vaccine efficacy in the JE vaccination subgroup could be largely explained by serotype-specific efficacy of TAK-003. Within 28 days of any vaccination, the proportions of participants with serious adverse events in the YF/JE prior vaccination population were comparable between the TAK-003 and placebo groups. Conclusions: The available data do not suggest a clinically relevant impact of prior JE or YF vaccination on TAK-003 performance. Overall, TAK-003 was well-tolerated and efficacious in different epidemiological settings. Clinical Trials Registration. NCT02747927.

First Page

e1214

Last Page

e1225

To view the document, please click the DOI link after the APA Citation.

Share

COinS